Bamifix®

BAMIFIX ® contains bamifylline, a methylxanthinic derivative with two side chains in position 7 and 8, distinguishing it clearly from theophylline .
Bamifylline carries out a bronchospasmolytic action on the smooth musculature and also blocks the action of the bronchoconstriction mediators.
The intensity of its bronchospasmolytic action is equal to that of theophylline.
Unlike theophylline, bamifylline usually has no exciting effects on the central nervous system.
Its pharmacokinetic characteristics are very interesting. Its absorption, both by oral and rectal route, is rapid, reaching the plasma peak between the first and the second hour. Its diffusion in the extravascular area is high, with a distribution volume equal to 1000 liters.
Bamifylline is rapidly metabolized to give 3 metabolites, also active and marked by high plasma concentrations. The prolonged activity of the drug allows for two daily administrations only.
Bamifylline final elimination half-life is of 17.5 hours. The excretion mostly occurs by urinary route.
Bamifylline shows a high therapeutical index, due to the wide interval between the minimum active and the maximum tolerated plasma levels (0.18 and 20 µg/ml, respectively).
The twice-daily administration of bamifylline leads to plasma levels of steady-state within 3-5 days both for bamifylline and its metabolites.

INDICATIONS
Bronchial asthma, pulmonary affections with bronchospastic component.

CONTRAINDICATIONS
Acute myocardial infarction.
known hypersensitivity to the product and to xanthinic derivatives.

DOSAGE
Usually 1 dragée of BAMIFIX ® in the morning and one in the evening before meals. Dosage can vary from 900 to 1800 mg daily according to medical advice.
Do not administer the drug at short intervals.

PRECAUTIONS AND WARNINGS
BAMIFIX ® dragées should not be administered to neonates and children in the first infancy, patients with severe heart failure, serious hypertension, hepatic and renal insufficiency, gastric ulcer and hyperthyroidism.

BAMIFIX ® should not be administered to children.
Tests on reproduction showed that bamifylline hydrochloride does not influence fertility, pregnancy, lactation and the embryofoetal development. However, it is advisable not to administer the drug during the first months of pregnancy, as a precautionary measure.
Under treatment with bamifylline, during pregnancy, no cases of neonatal toxicity were observed. However, it is advisable not to take the drug during the last days of pregnancy and during lactation.

SIDE EFFECTS
Cases of headache or gastralgia were seldom reported.
Doses higher than the therapeutical ones can induce the onset of nausea and slight distal tremors disappearing with therapy reduction.
Allergic reactions such as urticaria, itching, rash, dermatitis have been observed.

INTERACTIONS
No interactions with bamifylline are known, however, those known for theophylline should be considered.
Erythromycin, TAO lincomycin, clindamycin, allopurinol, cimetidine, antiflu vaccine and propranolol can increase the serum concentration of theophylline; phenytoin, other anticonvulsants and cigarette's smoking can decrease theophylline serum levels.
The product should not be administered with other xanthinic compounds.
Caution should be taken in case of combination with ephedrine or other sympathomimetic bronchodilators.

Keep out of the reach of children.

HOW SUPPLIED
BAMIFIX ®: box of 30 dragées (600 mg)

Chiesi

Manufactured by:
Hansel Pharmaceuticals (Pvt.) Ltd.
Plot No.2, Pharma City, 30 Km. Multan Road,
Sundar, Lahore - Pakistan.

Under Licence of:
CHIESI FARMACEUTICI S.p.A. - 26/A,Via Palermo - PARMA, ITALY.

بیمی فکس گولیاں

بیمی فائلین 600 ملی گرام

بیمی فکس بیمی فائلین کے عامل جز پر مشتمل میتھائل زینتھینک ڈیریویٹو ہے۔ جس کے ساتھ دو سائیڈ چین پوزیشن 7-8 پر ہیں۔ جو اسے واضح طور پر تھیوفائلین سے مختلف کرتے ہیں۔ بیمی فائلین سانس کی نالیوں کو کھولتی ہے اور سانس کی نالیوں کو تنگ کرنے والے میڈی ایٹر کے عمل کو بھی روکتی ہے بیمی فکس کی سانس کی نالیوں کو کھولنے کی طاقت تھیوفائلین کے مساوی ہے۔ تھیو فائلین کی طرح عموماً بیمی فائلین کے ساتھ سینٹرل نروس سسٹم پر ایکسائٹنگ افیکٹ یا ہیجان پیدا نہیں ہوتا۔

علامات:

دمہ، سانس کی نالیوں میں تنگی محسوس کرنے کی کیفیت۔

خوراک:

ایک گولی (ڈریجی) صبح اور شام کھانے سے پہلے۔ دوا کو ڈاکٹر کے تجویز کرنے پر 900 سے 1800 ملی گرام تک بڑھایا جاسکتا ہے۔ دوا کے دورانیہ کو کم کر کے استعمال نہ کریں۔

ممانعت برائے علاج:

(Myocardial Infarction) دل کے پٹھوں میں خون کی سپلائی بند ہونے کی وجہ سے کسی ایک حصے کی شدید صورت، کسی کو دوا میں موجود کسی جزیا زینتھینک ڈیریویٹو (Xanthinic derivative) سے ذو حسی (Hypersensitivity) ہو۔

پیکنگ:

بیمی فکس کے ایک پیک میں 600 ملی گرام کی 30 گولیاں (ڈریجی) ہوتی ہیں۔

ہدایات:

خوراک ڈاکٹر کی ہدایت کے مطابق استعمال کریں۔
صرف مستند ڈاکٹر کے نسخہ پر ہی دوا فروخت کی جائے۔
تمام ادویات بچوں کی پہنچ سے دور رکھیں۔
دوا کو 30°C سے کم درجہ حرارت پر نمی اور روشنی سے محفوظ رکھیں۔

Chiesi

CHIESI FARMACEUTICI S.p.A. - 26/A,Via Palermo - PARMA, ITALY.